anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: Aromatase plays an important role in ovarian development, the normal progress of the menstrual cycle, and fertility status. Elevated aromatase activity is linked to obesity. There is a bidirectional relationship between obesity and thyroid function. Few studies have investigated the relationship between TSH and ovarian aromatase in obesity. Our aim was to investigate the effect of TSH on aromatase expression of ovarian granulosa cells in obese mice.
METHODS: Female mice pups were divided into an obesity group and a control group. Obese parameters and the time of pubertal onset were recorded. At the age of 5 weeks, blood and tissues were obtained. Serum aromatase and hormone concentrations were measured using ELISA. The granulosa cells were isolated and exposed to variable concentrations (0 μM, 1 μM, 10 μM, 100 μM) of TSH. The expression of CYP19A1 mRNA and protein were assessed via RT-qPCR and western blot.
RESULTS: In female mice, body weight, Lee's obesity index, and serum levels of E2, aromatase, and TSH were significantly higher in the obesity group compared to the control group, whereas the time of pubertal onset and serum T3 and T4 concentrations were significantly lower (all P < 0.001). In granulosa cells, the expression of CYP19A1 mRNA in the obesity group was lower than that in the control group at 1 μM and 100 μM concentrations of TSH (both P < 0.001). The expression of CYP19A1 protein in the obesity group was higher than that in the control group after TSH stimulation (P = 0.014, P < 0.001, and P = 0.004, respectively). With the increase of TSH concentrations, the expression of CYP19A1 mRNA and protein in the two groups significantly increased (all P < 0.001).
CONCLUSION: Early puberty and elevated serum aromatase and TSH levels were found in obese female mice. In the granulosa cells of obese mice, TSH directly regulates aromatase expression in a dose-dependent manner.
At risk participants who test negative for the SCA10 mutation will serve as non-carriers. Exclusion criteria described above also applies to non-carrier subjects. If the number of non-carriers were less than 10, we will recruit additional participants from normal population to supplement the controls.
This study investigated whether the progression of liver fibrosis affects the prevalence of sarcopenia and incidence of decreased gait speed in older patients with chronic liver disease (CLD). Patients with CLD aged ≥ 60 years were classified into low, intermediate, and high fibrosis 4 (FIB-4) index groups according to the degree of liver fibrosis. The prevalence of sarcopenia and incidence of decreased gait speed (< 1.0 m/s) were compared among the three groups. Logistic regression analysis was performed to investigate factors affecting the risk of decreased gait speed. No significant difference was observed in the prevalence of sarcopenia among the three groups, but the incidence of decreased gait speed significantly differed (p = 0.029). When analyzed individually, a significant difference in decreased gait speed incidence was observed between the high and low FIB-4 index groups (p = 0.014). In logistic regression analysis, the progression of liver fibrosis (odds ratio: 1.32, 95% confidence interval: 1.13-1.55) and lower extremity muscle strength (LEMS) (odds ratio: 0.92, 95% confidence interval: 0.88-0.97) were significantly associated with decreased gait speed. As liver fibrosis progresses in older patients with CLD, it becomes important to focus on not only skeletal muscle mass and grip strength, but also gait speed and LEMS.
<P>PROBLEM TO BE SOLVED: To provide a preparation with which a consumer realizes an antiaging function.  <P>SOLUTION: The subject skin function ameliorant comprises an extract of Malus baccata var. mandschuria. The ameliorant is an antiaging preparation which satisfactorily exhibits bleaching effect and prevention effect on wrinkles of the extract of Malus baccata var. mandschuria.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
The present invention relates to hippophae rhamnoides fruit yolk health oil and a producing method thereof. The hippophae rhamnoides fruit yolk health oil has main ingredients of 75% to 85% of hippophae rhamnoides seeds, 8% to 14% of egg yolk powder and 7% to 11% of quail yolk powder. Yolk is taken from eggs and quail eggs and is dried and pulverized, and hippophae rhamnoides seeds are dried and pulverized. Alcohol is added to the yolk of the egg, the yolk of the quail egg and the hippophae rhamnoides seeds to be extracted. Then, extracted substance is concentrated, and the alcohol is recovered. 98% of extracted concentrated solution, 1.5% to 1.9% of beta-carotene and 0.1% to 0.5% of taurine are evenly mixed to be processed into capsules. The product contains rich unsaturated fatty acid, egg lecithin, fat-soluble vitamins and taurine. The present invention has a certain curative effect on therapeutic treatment and health care for cardiovascular diseases.
PROBLEM TO BE SOLVED: To effectively attain prevention of the side-effect of 5-flurouracil(5-FU), for example hypoleukocytosis by administering chitin chitosan in a specific form in a specific carcinostatic method using 5-FU and chitin chitosan. SOLUTION: In a carcinostatic method in which (A) 5-FU and (B) chitin chitosan are orally used in combination, at least the component B is given in the enteric form to suppress the side-effect of the 5-FU. The amount of the component B is 3-40-fold in weight, particularly 12-60-fold based on the component A in weight. In a preferred embodiment, the enteric form of the component B is prepared as capsules, tables or resinates. In the capsule preparation, the component A is used as a core capsule component, and the core component A is surrounded with the outer capsule of the component B to form a double capsule structure. Or, in another embodiment, a capsule is divided into two sections and these sections are filled with the components A and B separately.
Techniques may include displaying a user interface for a digital pathology platform and displaying a slide panel on the user interface. A thumbnail of a digitized image of a specimen can be displayed. A settings button can be displayed. An operation can be received on the settings button. A settings window can be displayed in response to receiving the operation on the settings button. One or more setting operations can be received via the settings window. One or more interactive icons associated with the slide panel can be displayed based on the one or more setting operations via the settings window. The one or more interactive icons can indicate status associated with the slide panel.
The treatment protocol the study team will be following is as follows for all enrolled patients. First, a pulse spray tPA infusion with 20 cc of 8 mg tPA and saline will be administered to the thrombus with a 20-minute dwell time. Afterwards, an 8F curved sheath (Indigo 8 Torq Tip, ranges 85 to 115 cm) with CAT8 penumbra device will be used to aspirate the thrombus. If the operating physician deems necessary, they will have the option at that point to balloon plasty, stent, or use catheter-directed thrombolysis at this point. Clinical parameters such as areas of clinically-significant stenosis, extent of thrombus, (more parameters) will be tracked at the time of the procedure. The device is being used is FDA approved and being used according to FDA indications.
Veterinary preparations for the treatment or prevention of coccidiosis comprises 2-chloro-4-nitrobenzamide and a physiologically innocuous carrier.  Optional additions are (a) other coccidiostats such as 2-sulphanilamidoquin-oxaline and (b) growth or egg production pro-motors such as penicillin and 4-hydroxy-3-nitrophenyl-arsenic acid.  The carrier may be solid, semi-solid or liquid and may be drinking water or an animal foodstuff, e.g. starting, laying or growing mash for poultry feed. Such feeds contain 0.001 to 0.1 and preferably 0.005 to 0.05% of the 2-chloro-4-nitrobenzamide. Concentrates for addition to poultry feed may contain 1 to 90% of the active ingredient.  Such concentrates may be prepared with a liquid carrier such as water or a solid carrier such as kaolin and chalk together, if desired, with a wetting, dispersing or emulsifying agent such as sodium lauryl sulphate and polyethylene (20) sorbitan monooleate.
UNLABELLED: This study investigates the effects of antiresorptive drugs and risk factors for medication-related osteonecrosis of the jaws in osteoporotic patients undergoing tooth extraction. Among the findings, antiresorptive-treated patients had thicker lamina dura and longer healing times. Additionally, corticosteroid intake and multi-rooted teeth carried a higher osteonecrosis risk. Bone sequestrum indicated osteonecrosis.
PURPOSE: To describe the effects of antiresorptive drugs (ARD) in the maxilla and mandible and risk factors for medication-related osteonecrosis of the jaws (MRONJ) in osteoporotic patients undergoing tooth extractions using clinical data and cone beam computed tomography (CBCT).
METHODS: This retrospective cohort study collected clinical and CBCT data from 176 patients. The study group (n = 78; 224 extractions) received ARD treatment, underwent tooth extraction, and had a pre-operative CBCT. Additionally, age-, sex-, and tooth-matched controls were selected (n = 98; 227 extractions). Radiographic examinations were performed independently by three calibrated examiners. Statistical analysis included Chi-square, Fisher's exact, Mann-Whitney U, and t-tests to contrast clinical and radiographic data between study and control, MRONJ + and MRONJ - , and bisphosphonate and denosumab patients/sites. Significance was set at p ≤ 0.05.
RESULTS: From the study group, 4 patients (5%) and 5 sites (2%) developed MRONJ after tooth extraction. ARD-treated patients exhibited significantly more thickening of the lamina dura and a longer average mucosal healing time (4.4 weeks) than controls (2.6 weeks). In the study group, MRONJ risk significantly increased with corticosteroid intake and in multi-rooted teeth. No significant differences between bisphosphonates and denosumab use were seen in the tomographic features (p > 0.05). Lastly, bone sequestrum was exclusively observed in osteoporotic patients, who exhibited post-operative exposed bone or histological evidence of osteonecrosis.
CONCLUSION: Osteoporotic patients under ARD may exhibit thickening of the lamina dura and prolonged post-operative healing. Among these patients, multi-rooted teeth are at higher risk for MRONJ than single-rooted teeth. Sequester formation is a radiographic indicator of osteonecrosis.
Needle localizations for breast cancer surgery are required to identify cancerous tissue before surgery. Currently this procedure is done with or without a local anesthetic. Patients report anxiety regarding cancer and cancer-related procedures. Different types of needle localization may have different pain and anxiety based on their duration, complexity, and invasiveness. This research is designed to determine if VR simulated environment can reduce pain and anxiety.

Our aim is to study the efficacy of a virtual environment in reducing pain and procedural anxiety. It is intended for patients undergoing an ultrasound guided breast localization procedure that have had an abnormal breast biopsy. The overall aim is to discover an efficacious nonpharmacologic method to lower pain and anxiety during a standard of care procedure.
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive interstitial lung disease (ILD) whose cause and pathogenesis are not yet well understood. Until now, no animal model of lung fibrosis succeeds in recapitulating all IPF features, thus the use of different rodent models is essential for the evaluation and development of new effective pharmacological treatments. Recently, the alveolar epithelial dysfunction has been emphasized in the etiopathogenesis context of IPF. Remarkably, the role of an aberrant basaloid cell type, primarily found in humans and confirmed in mice, seems to be crucial in the establishment and progression of the disease/model. Our work aimed to characterize for the first time this cell population in a rat model of lung fibrosis induced by a double bleomycin (BLM) administration, demonstrating the translational value of the model and its potential use in the testing of effective new drugs.
METHODS: Rats received an intratracheal BLM administration at day 0 and 4. Animals were sacrificed 21 and 28 days post-BLM. The fibrosis evaluation was carried out through histological (Ashcroft score and automatic image analysis) and immunoenzymatic analysis. Immunofluorescence was used for the characterization of the aberrant basaloid cells markers.
RESULTS: Lung histology revealed an increase in severe grades of Ashcroft scores and areas of fibrosis, resulting in a rise of collagen deposition at both the analyzed time-points. Immunofluorescence staining indicated the presence of KRT8+ cells in bronchial epithelial cells from both controls (saline, SAL) and BLM-treated animals. Interesting, KRT8+ cells were found exclusively in the fibrotic parenchyma (confirmed by the alpha-smooth muscle actin (α-SMA) staining for myofibroblasts) of BLM-treated animals. Moreover, KRT8+ cells co-expressed markers as Prosurfactant protein C (Pro-SPC) and Vimentin, suggesting their intermediate state potentially originating from alveolar type II (AT2) cells, and participating to the abnormal epithelial-mesenchymal crosstalk.
CONCLUSION: Previous preclinical studies demonstrated the presence of KRT8+ aberrant basaloid-like cells in murine models of lung fibrosis. This work investigated the same cell population in a different rodent (the rat) model of lung fibrosis triggered by a double administration of BLM. Our results provided a further confirmation that, in rats, the intratracheal administration of BLM induced the appearance of a population of cells compatible with the KRT8+ alveolar differentiation intermediate (ADI) cells, as described previously in the mouse. This piece of work enforces previous evidence and further support the use of a rat model of BLM resembling the alveolar epithelial dysfunction to evaluate new clinical candidates for development in IPF.
Risk Summary

DELFLEX solutions consist of electrolytes, lactate, and bicarbonate at physiological levels, and glucose to facilitate ultrafiltration. While there are no adequate and well controlled studies in pregnant women, appropriate administration of DELFLEX with monitoring of fluid, electrolyte, acid-base and glucose balance, is not expected to cause fetal harm. Animal reproduction studies have not been conducted with DELFLEX.

The estimated background risk of major birth defects and miscarriage for the indicated population are unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
BACKGROUND: Antivirals have been given widely for patients with COVID-19 breakthrough in Asian countries, creating a "black market" for unapproved and unprescribed medications. More evidence is needed to clarify the benefits of antivirals in these settings.
METHODS: We conducted a random-sampling retrospective cohort study at a general hospital in Vietnam. We recruited patients with mild-to-moderate COVID-19 breakthrough who were given either standard of care (SoC) alone or SoC + antiviral. Primary outcome was residual respiratory symptoms that lasted > 7 days. Secondary outcome was long COVID-19, diagnosed by specialized physicians. We used logistic regression to measure odds ratio (OR), in addition to a sensitivity and subgroup analyses to further explore the results.
RESULTS: A total of 142 patients (mean age 36.2 ± 9.8) were followed. We recorded residual symptoms in 27.9% and 20.3% of the SoC and SoC + antiviral group, while the figures for long COVID-19 were 11.8% and 8.1%, respectively. Antiviral use was not significantly associated with lower the risks of residual symptoms (OR = 0.51, 95% CI: 0.22-1.20, p = 0.12) or long COVID-19 (OR = 0.55, 95% CI: 0.16-1.90, p = 0.35). The sensitivity and subgroup analyses did not show any significant differences between the study groups (all p > 0.05).
CONCLUSION: Antivirals were not associated with faster resolution of respiratory symptoms or lower risks of long COVID-19. Further studies should focus on different antivirals to confirm their effects on different sub-populations. Meanwhile, antivirals should only be used in very high-risk patients to avoid excessive costs and harms.
Polymers are made by polymerization, e.g. in bulk, solution, or aqueous media, in the presence of a catalyst comprising a salt of sulphinic acid with an organic base and optionally a percompound and an additional reducing agent.  In bulk, preformed polymers, e.g. methyl methacrylate may be present.  Specified monomers are styrene, acrylic and methacrylic acids, acrylonitrile, methacrylonitrile and methyl methacrylate.  The salts may be those of isoamylsulphinic acid, n-octylsulphinic acid, benzenesulphinic acid or p-toluenesulphinic acid with methylamine, diethylamine, dibutylamine, diisobutylamine, dihexylamine, trihexylamine, aniline, p-toluidine, piperidine, or phenyl hydrazine.  Specified percompounds are hydrogen peroxide, potassium persulphate, dibenzoyl peroxide and p-chlorbenzoyl peroxide.  Additional reducing agents mentioned are tertiary amines, aryalkyldialkyl amines such as phenyl-ethyl-dibutyl amine and phenyl-butyl-dibutyl amine, tertiary alkanolamines, such as dibutyl-monoethanol amine, butyl-diethanolamine and triethanolamine, and the catalysts mentioned in Specification 708,077.  The polymers may be used in lacquers, adhesives, impregnants for fabrics, and moulded into safety glass, filters, spectacle lenses, artificial teeth and dental fillings.
Beginning on day 1, patients receive topotecan IV continuously for 3-6 weeks and thoracic radiotherapy 5 days a week for 2, 3, or 6 weeks. Cohorts of 4-6 patients receive escalating doses of topotecan and thoracic radiotherapy until the maximum tolerated dose (MTD) of each therapy is determined. The MTD is defined as the dose preceding that at which 2 of 4 or 6 patients experience dose-limiting toxicity. Six additional patients are treated at the MTD. Patients who fail to achieve complete remission (CR) and continue to have measurable disease at 4-6 weeks after completion of radiotherapy receive topotecan IV continuously on days 1-21 at 1 dose level preceding the MTD as determined by the ongoing Protocol NYU-9123. Treatment continues every 4 weeks in the absence of unacceptable toxicity.
In case of overdosage, discontinue medication, treat symptomatically, and institute supportive measures as required. A prospective study of 51 pediatric patients at a poison-control center suggested that overdosages of less than 250 mg/kg of amoxicillin are not associated with significant clinical symptoms1.

Interstitial nephritis resulting in oliguric renal failure has been reported in patients after overdosage with amoxicillin/clavulanate potassium.

Crystalluria, in some cases leading to renal failure, has also been reported after amoxicillin and clavulanate potassium overdosage in adult and pediatric patients. In case of overdosage, adequate fluid intake and diuresis should be maintained to reduce the risk of amoxicillin/clavulanate potassium crystalluria.

Renal impairment appears to be reversible with cessation of drug administration. High blood levels may occur more readily in patients with impaired renal function because of decreased renal clearance of amoxicillin and clavulanate potassium. Amoxicillin and clavulanate potassium may be removed from circulation by hemodialysis. [see Dosage and Administration (2.4)]
A medicine for external use and for treating psoriasis is disclosed. The medicine is prepared from following raw materials by weight: 15-20 parts of sapium sebiferum, 10-15 parts of fossil shell of spirifer, 15-20 parts of spora lygodii, 5-9 parts of cypress sawdust, 15-25 parts of cypress resin, 5-8 parts of herba taxilli, 5-8 parts of gingko nut, 10-13 parts of radix angelicae pubescentis, 2-6 parts of crocus sativus and 6-10 parts of snake bile. Compared with medicines at present, the medicine has a high curative rate for psoriasis, relieves disease symptoms in a short period of time, and has significant treating effects. The fossil shell of spirifer has functions of dispelling wind, detoxifying and killing pests, treats rheumatic arthritis and skin itching by external application, kills maggots and oncomelania and poisons rats. The spora lygodii has functions of opening all body orifices, dispersing stagnated fire, relieving swelling and pain, clearing away heat and toxic materials, purging fire and detoxifying. The medicine has advantages of a simple, stable and easily mastered preparation process, saved investment, simple operation, a short production period, and the like.
All subjects will receive induction oral curcumin 500 mg twice per day for 2 weeks. Patients will continue on curcumin at same dose for an additional 6 weeks while being treated with 3 cycles of 5FU.
<P>PROBLEM TO BE SOLVED: To obtain a new antineoplastic agent as a new means for the treatment of cancer.  <P>SOLUTION: This antineoplastic agent contains docosapentaenoic acid (DPA). The antineoplastic agent develops high utility especially by the combined use with an immunotherapeutic agent for cancer. Harp seal oil containing ≥7% docosapentaenoic acid and known as "Docopen(R)" is a useful antineoplastic agent. An extremely useful antineoplastic agent is produced by the combined use with an IL-12 production inducing agent useful as an immunotheapeutic agent for cancer such as a substance having a β-1,3/1,6 glucan structure.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
The Chinese version of Demoralization Scale-Mandarin Version (DS-MV) was used to assess the mental state of patients with stroke after debridement. The statistical analysis test of correlation is carried out, and the reliability and validity test and the norm establishment of the Chinese version are further tested. Convenient sampling will be performed at a single medical facility. The planned implementation period is 2019/01/01 \~ 2019/12/31, and the location of the case is the rehabilitation ward and outpatient clinic of Taoyuan Hospital. The diagnosis must be: intensive stroke or hemorrhagic brain within three years. In the case of a 20- to 100-year-old clinical patient with stroke, the subject should explain the content of the case, and the subject will complete the test consent form after informed consent, and then begin the evaluation process of the self-assessment questionnaire. The assessment procedure is preceded by a clinical psychologist conducting with MMSE test to determine the cognitive function. When the patient's consciousness is blurred, the simple intelligent state test (MMSE) score less than 24 points, aphasia can not be effectively communicated, the diagnosis of mental illness or mental disorder has been recorded on the medical record, or the patient or family member is unwilling to sign the informed consent form. If the above situation is met, subjects will be excluded. The self-assessment questionnaire will obtain the scores of the subjects in the Chinese version of the Demoralization Scale-Mandarin Version (DS-MV) and the Patient Health Questionnaire (PHQ-9). Statistical analysis, as well as the Chinese version of the loss of the scale of the reliability and validity of the test and the establishment of clinical norm scores.